Abstract
The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Bone Marrow / drug effects
-
Breast Neoplasms / drug therapy*
-
Drug Evaluation
-
Drug Resistance
-
Drug Therapy, Combination
-
Female
-
Humans
-
Middle Aged
-
Mitomycins / administration & dosage*
-
Mitomycins / adverse effects
-
Neoplasm Metastasis
-
Vinblastine / administration & dosage*
-
Vinblastine / adverse effects
Substances
-
Antineoplastic Agents
-
Mitomycins
-
Vinblastine